Otsuka Pharmaceutical

To see an up-to date selection of historical analyses and insights on Otsuka Pharmaceutical, visit our new, dynamically updated Company Summary report pages for Otsuka Pharmaceutical.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Otsuka Pharmaceutical are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Otsuka Pharmaceutical, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Event - GW will expand on Sativex approval   (GW Pharmaceuticals)   (Invalid Date)
Acucela Launches ENVISION Clarity Trial   (Acucela)   (Invalid Date)
Sativex® Phase II/III Cancer Pain Study Completes Patient Recruitment Sativex® Phase II/III Cancer Pain Study Completes Patient Recruitment   (GW Pharmaceuticals)   (Invalid Date)
Acucela Data in Dry AMD to be Highlighted at the 8th International Symposium on Ocular Pharmacology and Therapeutics   (Acucela)   (Invalid Date)
Positive Results from Clinical Study of Sativex(R) in Cancer Pain Published in Peer Review Journal   (GW Pharmaceuticals)   (Invalid Date)
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)   (Bristol-Myers Squibb)   (Invalid Date)
Penwest Formulation Demonstrates Proof-of-Principal in Phase I Trial in Development Program With Otsuka Pharmaceutical   (Penwest Pharmaceuticals)   (Invalid Date)
Otsuka Pharmaceutical Factory Announces HINE® Jelly AQUA   (Otsuka Pharmaceutical)   (Invalid Date)
Otsuka Pharmaceutical Factory Released ELNEOPA No. 1 Injection & ELNEOPA No. 2 Injection - the World's First TPN* Solution Formulated With Five Types of Trace Elements   (Otsuka Pharmaceutical)   (Invalid Date)
MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat)   (MethylGene)   (Invalid Date)
New Addition to CalorieMate® Line of Balanced Nutrition Blocks CalorieMate® Block, Maple Flavor   (Otsuka Pharmaceutical)   (Invalid Date)
The European Commission Approves Samsca(™) (tolvaptan), Europe’s First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)   (Otsuka Pharmaceutical)   (Invalid Date)
TS-1 Approved in Singapore   (Otsuka Pharmaceutical)   (Invalid Date)
FDA Approves SAMSCA(™) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia   (Otsuka Pharmaceutical)   (Invalid Date)
Acucela Founder to Present at BIO Business Forum   (Acucela)   (Invalid Date)
Acucela Presents Dry AMD Therapy Data at ARVO   (Acucela)   (Invalid Date)
Therapeutic focus - Real innovation in antipsychotics is on distant horizon   (Vanda Pharmaceuticals)   (Invalid Date)
Acucela Highlights Data to be Presented at ARVO   (Acucela)   (Invalid Date)
Antipsychotic agent ABILIFY® Oral Solution 0.1% to be Launched on April 10, 2009 in Japan   (Otsuka Pharmaceutical)   (Invalid Date)
Acucela Founder to Speak at Ophthalmology Conference   (Acucela)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.